Across TCGA pan-cancer cohorts, DEFB104A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB104A data layer compared with 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DEFB104A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEFB104A expression acts as an unfavorable survival marker.
SKCM are the cancer types where DEFB104A Mutation most reproducibly stratifies survival.